Misplaced Pages

Prusogliptin

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2023)
Pharmaceutical compound
Prusogliptin
Clinical data
Other namesDBPR108
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • (2S,4S)-4-Fluoro-1-acetyl]pyrrolidine-2-carbonitrile
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC16H25FN4O2
Molar mass324.400 g·mol
3D model (JSmol)
SMILES
  • CC(C)(CC(=O)N1CCCC1)NCC(=O)N2C(C2C#N)F
InChI
  • InChI=1S/C16H25FN4O2/c1-16(2,8-14(22)20-5-3-4-6-20)19-10-15(23)21-11-12(17)7-13(21)9-18/h12-13,19H,3-8,10-11H2,1-2H3/t12-,13-/m0/s1
  • Key:VQKSCYBKUIDZEI-STQMWFEESA-N

Prusogliptin (DBPR108) is an experimental DPP-4 inhibitor developed by CSPC Pharmaceutical Group to treat type 2 diabetes.

References

  1. Xu, Jianping; Ling, Hongwei; Geng, Jianlin; Huang, Yanli; Xie, Ying; Zheng, Huiping; Niu, Huikun; Zhang, Tianhao; Yuan, Jing; Xiao, Xinhua (November 2022). "Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial". Diabetes, Obesity and Metabolism. 24 (11): 2232–2240. doi:10.1111/dom.14810. PMC 9796963. PMID 35791646.
  2. Yeh, Kai-Chia; Yeh, Teng-Kuang; Huang, Chung-Yu; Hu, Chih-Bo; Wang, Min-Hsien; Huang, Yu-Wen; Chou, Ling-Hui; Ho, Hsuan-Hui; Song, Jen-Shin; Hsu, Tsu; Jiaang, Weir-Torn; Chao, Yu-Sheng; Chen, Chiung-Tong (August 2021). "DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity". Life Sciences. 278: 119574. doi:10.1016/j.lfs.2021.119574. PMID 33961850. S2CID 233999305.
  3. Wang, Wei; Yao, Jun; Guo, Xiaohui; Guo, Yushan; Yan, Chaoli; Liu, Kuanzhi; Zhang, Ying; Wang, Xiaoyue; Li, Hongmei; Wen, Zhongyuan; Wang, Xinling; Li, Shuangqing; Xiao, Xinhua; Liu, Weijuan; Li, Ziling; Zhang, Lihui; Shao, Shiying; Ye, Shandong; Qin, Guijun; Li, Yiming; Li, Feng; Zhang, Xiaomei; Li, Xuefeng; Peng, Yongde; Deng, Hongyan; Xu, Xiangjin; Zhou, Ligang; Huang, Yanli; Cao, Mengya; Xia, Xuefang; Shi, Mingbiao; Dou, Jing; Yuan, Jing (2 July 2020). "Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial". Current Medical Research and Opinion. 36 (7): 1107–1115. doi:10.1080/03007995.2020.1761311. PMID 32338063. S2CID 216555956.
Categories: